Inhibitors | Comment | Organism | Structure |
---|---|---|---|
2-PEPC | i.e.3-PEPC, protein geranylgeranyltransferase-II is the major pharmacological target of the inhibitor | Mus musculus | |
3-(1-methylpyridin-1-ium-3-yl)-2-phosphonopropanoate | i.e.NE1048 , protein geranylgeranyltransferase-II is the major pharmacological target of the inhibitor | Mus musculus | |
3-PEHPC | i.e.3-PEHPC, protein geranylgeranyltransferase-II is the major pharmacological target of the inhibitor | Mus musculus | |
3-PEPC | i.e.2-PEPC, protein geranylgeranyltransferase-II is the major pharmacological target of the inhibitor | Mus musculus | |
additional information | protein geranylgeranyltransferase-II is the major pharmacological target of phosphonocarboxylate inhibitors. Analysis of several different phosphonocarboxylate drugs demonstrates a very good correlation between the ability of these drugs to inhibit the enzyme with their ability to reduce macrophage cell viability and induce apoptosis | Mus musculus | |
risedronate | - |
Mus musculus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Mus musculus | - |
- |
- |
General Information | Comment | Organism |
---|---|---|
physiological function | cells from the gunmetal gm/gm mouse, which bear a homozygous mutation in protein geranylgeranyltransferase-II that results in about 80% reduced activity of this enzyme compared to wild-type or heterozygous mice, are more sensitive to the effects of active phosphonocarboxylates, including reducing macrophage cell viability, inhibiting osteoclast formation and inhibiting fluid-phase endocytosis | Mus musculus |